Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Director | June 06, 2023 | June 08, 2023 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director · CHIEF EXECUTIVE OFFICER | September 15, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OnKure Therapeutics, Inc.
Report date June 06, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.01 · Expires 2033-06-05 | Direct | 17,500 |
Reported balance
After 2023-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-06 · Grant · Acquired 17,500 · Balance 17,500 F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest on the earlier of June 6, 2024 or the day prior to the date of the Issuer's 2024 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Travere Therapeutics, Inc.
Report date September 15, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 432,886 |
Ending reported balance
After 2026-09-17 transaction · row 11
11 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 95,666 · Balance 528,552 Row 2 · 2026-09-15 · Sale · Disposed 63,498 · Balance 465,054 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F2: The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 3 · 2026-09-15 · Sale · Disposed 28,796 · Balance 436,258 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F3: The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 4 · 2026-09-15 · Sale · Disposed 3,102 · Balance 433,156 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F4: The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 5 · 2026-09-15 · Sale · Disposed 270 · Balance 432,886 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. Row 6 · 2026-09-16 · Exercise / conversion · Acquired 195,841 · Balance 628,727 Row 7 · 2026-09-16 · Sale · Disposed 99,716 · Balance 529,011 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F5: The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 8 · 2026-09-16 · Sale · Disposed 96,125 · Balance 432,886 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F6: The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 9 · 2026-09-17 · Exercise / conversion · Acquired 108,493 · Balance 541,379 Row 10 · 2026-09-17 · Sale · Disposed 101,691 · Balance 439,688 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F7: The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 11 · 2026-09-17 · Sale · Disposed 6,802 · Balance 432,886 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. F8: The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.34 · Expires 2029-01-04 | Direct | 304,334 |
Reported balance
After 2026-09-15 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-15 · Exercise / conversion · Disposed 95,666 · Balance 304,334 F9: The stock option is fully vested and exercisable. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.34 · Expires 2029-01-04 | Direct | 108,493 |
Reported balance
After 2026-09-16 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-16 · Exercise / conversion · Disposed 195,841 · Balance 108,493 F9: The stock option is fully vested and exercisable. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.34 · Expires 2029-01-04 | Direct | 0 |
Reported balance
After 2026-09-17 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-09-17 · Exercise / conversion · Disposed 108,493 · Balance 0 F9: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
F2: The weighted average sale price for the transaction reported was $61.9945, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: The weighted average sale price for the transaction reported was $62.6553, and the range of prices were between $62.41 and $63.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4: The weighted average sale price for the transaction reported was $63.6434, and the range of prices were between $63.45 and $63.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5: The weighted average sale price for the transaction reported was $63.2593, and the range of prices were between $62.51 and $63.505. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6: The weighted average sale price for the transaction reported was $63.6389, and the range of prices were between $63.51 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F7: The weighted average sale price for the transaction reported was $64.5866, and the range of prices were between $63.84 and $64.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F8: The weighted average sale price for the transaction reported was $64.9508, and the range of prices were between $64.84 and $65.14. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F9: The stock option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2020 Filed Feb 1, 2020 01:14 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005899 · doc4.xml · derivative · entry 3 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F3 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date. F3 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on January 31, 2024 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| January 31, 2020 Filed Feb 1, 2020 01:14 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 300,000 | $0.00 Strike: $15.46 | $0.00 |
DisclosureSEC source: 0001209191-20-005899 · doc4.xml · derivative · entry 2 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-01-30 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 31, 2020 Filed Feb 1, 2020 01:14 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005899 · doc4.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 Read SEC document |
| January 08, 2020 Filed Jan 9, 2020 01:49 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 3,750 | $15.14 | $56,775.00 |
DisclosureSEC source: 0001209191-20-002631 · doc4.xml · nonDerivative · entry 2 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 07, 2020 Filed Jan 9, 2020 01:49 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | SaleCommon Stock | 3,750 | $13.94 | $52,275.00 |
DisclosureSEC source: 0001209191-20-002631 · doc4.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 F1 · kind: The sales reported in this Form 4 were made pursuant to a written plan meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 09, 2019 Filed May 11, 2019 01:39 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-029173 · doc4.xml · derivative · entry 1 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F2 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. F2 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 22:25 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002858 · doc4.xml · derivative · entry 3 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F3 · derivative.exercise_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. F3 · derivative.expiration_date: This grant will vest upon the later of (i) 12 months from the date of grant, and (ii) the achievement of specified clinical and regulatory development milestones, provided that the grant will expire on May 9, 2023 to the extent the specified clinical and regulatory milestones are not achieved by such date. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 22:25 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee stock option (right to buy) · Derivative | 400,000 | $0.00 Strike: $23.34 | $0.00 |
DisclosureSEC source: 0001209191-19-002858 · doc4.xml · derivative · entry 2 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2029-01-03 F1 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 22:25 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-002858 · doc4.xml · nonDerivative · entry 1 Dube Eric M · CIK 0001763494 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.